General Info
Industry leader in investing in marketed and late stage biopharmaceutical products
Location: New York
Country:
Industries:
Investment Regions:
Investment Stages: late-stage
Website: http://royaltypharma.com/
vc
Want to start building warm intros with this investor?
🤖 AI Activity Report
Status: very-active
AI Reasoning: Royalty Pharma has multiple transaction press releases in 2025 (e.g., Jan 10, 2025 acquisition of its external manager; Feb 12, 2025 R&D funding collaboration with Biogen for litifilimab; Jun 24, 2025 funding agreements with Revolution Medicines for daraxonrasib; Aug 25, 2025 acquisition of royalty interest in Amgen’s Imdelltra). The most recent known investment/transaction is Sep 2, 2025 (Obexelimab funding agreement with Zenas Biopharma). This is less than 3 months prior to the target evaluation date, indicating very recent activity. The reasoning references Syndax’s Niktimvo and Geron’s Rytelo as additional 2024 investments for context.
Here are the thresholds established for the different statuses:
Not Active – No known investments in the last 12 months.
Low Activity – Only known investments between the last 12 and 6 months.
Active – Known investments between the last 6 and 3 months.
Very Active – Known investments in the last 3 months.
Investor Contact
Team Members
Name
Role
Email
LinkedIn
…
…
…
…
…
Investment Regions Map
loading map…
Similar Investors
Other similar investors:
Latest on X (Twitter)
Access all contact details of Royalty Pharma
Gain instant access to partner names, verified emails, LinkedIn profiles, and more—all in one place. Dive into their portfolio founders and their LinkedIn information, so you can quickly start your outreach and look for warm intros.
Add custom tags to your investor cards. Label them by investment stage, industry focus, interest level, or any other criteria you want to stay organized.
Trusted by Founders like You
Find your matching investors using AI